DE602005025514D1 - Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms - Google Patents

Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms

Info

Publication number
DE602005025514D1
DE602005025514D1 DE602005025514T DE602005025514T DE602005025514D1 DE 602005025514 D1 DE602005025514 D1 DE 602005025514D1 DE 602005025514 T DE602005025514 T DE 602005025514T DE 602005025514 T DE602005025514 T DE 602005025514T DE 602005025514 D1 DE602005025514 D1 DE 602005025514D1
Authority
DE
Germany
Prior art keywords
fms
methylpiperazin
ylamino
pyrimidin
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005025514T
Other languages
German (de)
English (en)
Inventor
Andrea Louis Dewar
Timothy Peter Hughes
Alan Bruce Lyons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of DE602005025514D1 publication Critical patent/DE602005025514D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602005025514T 2004-10-18 2005-10-17 Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms Expired - Lifetime DE602005025514D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18
PCT/AU2005/001602 WO2006042362A1 (en) 2004-10-18 2005-10-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Publications (1)

Publication Number Publication Date
DE602005025514D1 true DE602005025514D1 (de) 2011-02-03

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005025514T Expired - Lifetime DE602005025514D1 (de) 2004-10-18 2005-10-17 Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms

Country Status (19)

Country Link
US (1) US20080255139A1 (https=)
EP (1) EP1804800B1 (https=)
JP (1) JP2008516898A (https=)
KR (1) KR20070083705A (https=)
CN (1) CN101035535A (https=)
AT (1) ATE492277T1 (https=)
AU (1) AU2005297321A1 (https=)
BR (1) BRPI0517083A (https=)
CA (1) CA2580976A1 (https=)
DE (1) DE602005025514D1 (https=)
IL (1) IL182419A0 (https=)
MA (1) MA28946B1 (https=)
MX (1) MX2007004660A (https=)
NO (1) NO20072501L (https=)
NZ (1) NZ554009A (https=)
RU (1) RU2007118420A (https=)
TN (1) TNSN07141A1 (https=)
WO (1) WO2006042362A1 (https=)
ZA (1) ZA200702316B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058968A2 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
CN107530430A (zh) * 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
WO2004026930A2 (en) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt

Also Published As

Publication number Publication date
AU2005297321A1 (en) 2006-04-27
MA28946B1 (fr) 2007-10-01
NO20072501L (no) 2007-05-15
KR20070083705A (ko) 2007-08-24
NZ554009A (en) 2010-09-30
JP2008516898A (ja) 2008-05-22
IL182419A0 (en) 2007-09-20
TNSN07141A1 (en) 2008-11-21
EP1804800B1 (en) 2010-12-22
ZA200702316B (en) 2008-09-25
WO2006042362A1 (en) 2006-04-27
CA2580976A1 (en) 2006-04-27
EP1804800A4 (en) 2008-03-19
BRPI0517083A (pt) 2008-09-30
ATE492277T1 (de) 2011-01-15
EP1804800A1 (en) 2007-07-11
RU2007118420A (ru) 2008-11-27
CN101035535A (zh) 2007-09-12
MX2007004660A (es) 2007-10-17
US20080255139A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
NO20072501L (no) Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
JP2008542390A5 (https=)
IS2712B (is) Notkun týrósínkínasatálma til að meðhöndla sykursýki
RU2020127993A (ru) Терапевтическое средство для лечения гепатоцеллюлярной карциномы
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes
CL2008002461A1 (es) Compuesto 4-((trans)-2-(4-ciclobutilpiperazina-1-carbonil)ciclopropil)benzamida o un enantiómero, o una sal farmacéuticamente aceptable o una mezcla del mismo